ritonavir

Ritonavir metabolite is a Ritonavir metabolite, which is a inhibitor of HIV protease.

Paritaprevir free base (ABT-450) is an orally bioavailable, synthetic acylsulfonamide inhibitor of the hepatitis C virus (HCV) protease complex comprised of non-structural protein 3 and 4A (NS3/NS4A), with potential activity against HCV genotype 1. Upon administration, paritaprevir reversibly binds to the active center and binding site of the HCV NS3/NS4A protease and prevents NS3/NS4A protease-mediated polyprotein maturation. This disrupts both the processing of viral proteins and the formation of the viral replication complex, which inhibits viral replication in HCV genotype 1-infected host cells.

Ritonavir (ABT 538) is a peptidomimetic agent that inhibits both HIV-1 and HIV-2 proteases. Ritonavir is highly inhibited by serum proteins but boosts the effect of other HIV proteases by blocking their degradation by cytochrome P450.

Desthiazolylmethyl ritonavir is an alkaline-catalyzed degradation product of the HIV protease inhibitor Ritonavir.

Hydroxy ritonavir, a metabolite of ritonavir, functions as an inhibitor of the HIV protease, thereby serving as a treatment for HIV infection and AIDS [1].

Ritonavir-d6 is the deuterated form of Ritonavir. Ritonavir (ABT 538) serves as an inhibitor of the HIV protease, primarily utilized in the study of HIV infection and AIDS. Additionally, Ritonavir acts as an inhibitor of SARS-CoV 3CLpro, with an IC50 of 1.61 μM.

rel-Ritonavir-d6 (rel-ABT 538-d6; rel-RTV-d6) is a deuterated form of Ritonavir. Ritonavir (ABT 538) serves as an inhibitor of HIV protease, utilized in studies of HIV infection and AIDS. Additionally, Ritonavir acts as an inhibitor of SARS-CoV 3CLpro, with an IC50 of 1.61 μM.

Ritonavir (Standard) is a reference standard for research and analysis in studies involving Ritonavir. Ritonavir (ABT 538) is a peptidomimetic agent that inhibits both HIV-1 and HIV-2 proteases. Ritonavir is highly inhibited by serum proteins but boosts the effect of other HIV proteases by blocking their degradation by cytochrome P450.

Ritonavir-13C-d3 the 13C and deuterated compound of Ritonavir. Ritonavir has a CAS number of 155213-67-5. Ritonavir is a peptidomimetic agent that inhibits both HIV-1 and HIV-2 proteases. Ritonavir is highly inhibited by serum proteins but boosts the effect of other HIV proteases by blocking their degradation by cytochrome P450.

Lopinavir (ABT-378) is a peptidomimetic HIV protease inhibitor effective against HIV protease with the Val 82 mutation. It is less affected by serum protein binding compared to the structurally related drug ritonavir.

Ureidovaline is an intermediate in the Ritonavir synthesis.

CYP3A4-IN-3 is a specific, highly affinity cytochrome P450 3A4 (CYP3A4) (cytochrome P450 3A4 (CYP3A4)) inhibitor (IC50: 0.075 μM). CYP3A4-IN-3 is an analogue of ritonavir with a simpler structure and twice as much inhibition as ritonavir. CYP3A4-IN-3 can be used as an antiviral agent and immunosuppressant.

CYP3A4-IN-2 is a specific inhibitor of cytochrome P450 3A4 (CYP3A4) (IC50: 0.055 μM). As a ritonavir analogue with a more hydrophobic R2 side group, CYP3A4-IN-2 exhibits stronger inhibition than ritonavir and is capable of acting as an immunosuppressive and antiviral agent.

Paritaprevir dihydrate (ABT-450), a highly effective and orally administered antiviral, acts as a non-structural protein 3/4A (NS3/4A) protease inhibitor, displaying EC50 values of 1 and 0.21 nM against HCV genotypes 1a and 1b, respectively. Additionally, it functions as a SARS-CoV 3CL pro inhibitor with an IC50 of 1.31 μM. Primarily metabolized by cytochrome P450 (CYP) 3A, its plasma concentration and half-life are significantly increased when administered with Ritonavir, a CYP450 inhibitor [1] [2] [3] [4].

Lopinavir-d8 is a deuterated compound of Lopinavir. Lopinavir has a CAS number of 192725-17-0. Lopinavir is a peptidomimetic HIV protease inhibitor that retains activity against HIV protease with the Val 82 mutation. Lopinavir is less affected by binding to serum proteins than the structurally-related drug ritonavir.